Bacil Pharma [BACPHAR] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison
Bacil Pharma
BSE
Loading...
Divi's Laboratories
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Bacil Pharma wins in 6 metrics, Divi's Laboratories wins in 11 metrics, with 0 ties. Divi's Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bacil Pharma | Divi's Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 30.00 | 71.48 | Bacil Pharma |
| Price-to-Book Ratio | 1.13 | 10.99 | Bacil Pharma |
| Debt-to-Equity Ratio | 0.64 | 0.03 | Divi's Laboratories |
| PEG Ratio | -0.03 | 2.70 | Bacil Pharma |
| EV/EBITDA | -153.41 | 52.47 | Bacil Pharma |
| Profit Margin (TTM) | 111.61% | 23.89% | Bacil Pharma |
| Operating Margin (TTM) | -10.86% | 25.60% | Divi's Laboratories |
| EBITDA Margin (TTM) | N/A | 25.60% | N/A |
| Return on Equity | 1.59% | 14.64% | Divi's Laboratories |
| Return on Assets (TTM) | 1.58% | 12.94% | Divi's Laboratories |
| Free Cash Flow (TTM) | $4.01M | $2.15B | Divi's Laboratories |
| Dividend Yield | N/A | 0.91% | N/A |
| 1-Year Return | 92.79% | 20.37% | Bacil Pharma |
| Price-to-Sales Ratio (TTM) | 21.92 | 17.04 | Divi's Laboratories |
| Enterprise Value | $487.13M | $1,608.15B | Divi's Laboratories |
| EV/Revenue Ratio | 49.12 | 16.66 | Divi's Laboratories |
| Gross Profit Margin (TTM) | N/A | 60.33% | N/A |
| Revenue per Share (TTM) | $1 | $363 | Divi's Laboratories |
| Earnings per Share (Diluted) | $1.23 | $86.67 | Divi's Laboratories |
| Beta (Stock Volatility) | 0.30 | 0.27 | Divi's Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Bacil Pharma vs Divi's Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bacil Pharma | -1.60% | -1.60% | -1.81% | -11.19% | -11.53% | -30.72% |
| Divi's Laboratories | -0.01% | -0.33% | -8.16% | -7.54% | 11.88% | 0.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bacil Pharma | 92.79% | 766.20% | 1,146.62% | 476.56% | 638.00% | 246.48% |
| Divi's Laboratories | 20.37% | 70.41% | 90.23% | 463.36% | 1,520.59% | 8,066.62% |
Performance & Financial Health Analysis: Bacil Pharma vs Divi's Laboratories
| Metric | BACPHAR | DIVISLAB |
|---|---|---|
| Market Information | ||
| Market Cap | ₹217.34M | ₹1.64T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 29,436 | 432,095 |
| 90 Day Avg. Volume | 31,562 | 382,188 |
| Last Close | ₹36.90 | ₹6,131.50 |
| 52 Week Range | ₹16.24 - ₹62.56 | ₹4,955.00 - ₹7,071.50 |
| % from 52W High | -41.02% | -13.29% |
| All-Time High | ₹62.56 (Dec 16, 2024) | ₹7,071.50 (Jul 08, 2025) |
| % from All-Time High | -41.02% | -13.29% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.14% |
| Quarterly Earnings Growth | N/A | 0.27% |
| Financial Health | ||
| Profit Margin (TTM) | 1.12% | 0.24% |
| Operating Margin (TTM) | -0.11% | 0.26% |
| Return on Equity (TTM) | 0.02% | 0.15% |
| Debt to Equity (MRQ) | 0.64 | 0.03 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹32.60 | ₹563.87 |
| Cash per Share (MRQ) | ₹2.05 | ₹132.86 |
| Operating Cash Flow (TTM) | ₹4.03M | ₹19.67B |
| Levered Free Cash Flow (TTM) | ₹4.04M | ₹21.91B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.91% |
| Last 12-Month Dividend | N/A | ₹60.00 |
Valuation & Enterprise Metrics Analysis: Bacil Pharma vs Divi's Laboratories
| Metric | BACPHAR | DIVISLAB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 30.00 | 71.48 |
| Forward P/E | N/A | 110.04 |
| PEG Ratio | -0.03 | 2.70 |
| Price to Sales (TTM) | 21.92 | 17.04 |
| Price to Book (MRQ) | 1.13 | 10.99 |
| Market Capitalization | ||
| Market Capitalization | ₹217.34M | ₹1.64T |
| Enterprise Value | ₹487.13M | ₹1.61T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 49.12 | 16.66 |
| Enterprise to EBITDA | -153.41 | 52.47 |
| Risk & Other Metrics | ||
| Beta | 0.30 | 0.27 |
| Book Value per Share (MRQ) | ₹32.60 | ₹563.87 |
Financial Statements Comparison: Bacil Pharma vs Divi's Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BACPHAR | DIVISLAB |
|---|---|---|
| Revenue/Sales | ₹0 | ₹24.10B |
| Cost of Goods Sold | N/A | ₹9.56B |
| Gross Profit | N/A | ₹14.54B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-1.09M | ₹6.17B |
| EBITDA | ₹-1.09M | ₹8.48B |
| Pre-Tax Income | ₹8.94M | ₹7.33B |
| Income Tax | ₹2.25M | ₹1.88B |
| Net Income (Profit) | ₹6.69M | ₹5.45B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BACPHAR | DIVISLAB |
|---|---|---|
| Cash & Equivalents | ₹28.57M | ₹4.15B |
| Total Current Assets | ₹29.08M | ₹100.81B |
| Total Current Liabilities | ₹1.69M | ₹14.52B |
| Long-Term Debt | N/A | ₹20.00M |
| Total Shareholders Equity | ₹254.31M | ₹149.69B |
| Retained Earnings | N/A | ₹134.00B |
| Property, Plant & Equipment | N/A | ₹3.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BACPHAR | DIVISLAB |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BACPHAR | DIVISLAB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 29,436 | 432,095 |
| Average Daily Volume (90 Day) | 31,562 | 382,188 |
| Shares Outstanding | 5.89M | 265.47M |
| Float Shares | 12.10M | 120.74M |
| % Held by Insiders | 0.15% | 0.52% |
| % Held by Institutions | 0.00% | 0.29% |
Dividend Analysis & Yield Comparison: Bacil Pharma vs Divi's Laboratories
| Metric | BACPHAR | DIVISLAB |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹60.00 |
| Last 12-Month Dividend Yield | N/A | 0.91% |
| 3-Year Avg Annual Dividend | N/A | ₹50.00 |
| 3-Year Avg Dividend Yield | N/A | 0.70% |
| 3-Year Total Dividends | N/A | ₹150.00 |
| Ex-Dividend Date | N/A | Jul 25, 2025 |